We are live on ! Find out more
DMK

David M. Knott Portfolio holdings

AUM $275M Turnover 23.21%
1-Year Est. Return 59.23%
This Fund
S&P 500
This Quarter Est. Return
+7.42%
1 Year Est. Return
+59.23%
3 Year Est. Return
+80.95%
5 Year Est. Return
+223.18%
10 Year Est. Return
–
AUM
$240M
AUM Growth
+$31.8M
Cap. Flow
+$17.7M
Cap. Flow %
7.4%
Top 10 Hldgs %
80.41%
Holding
94
New
15
Increased
22
Reduced
3
Closed
4
Avg Time Held
2 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$2.06M
2
HHH icon
Howard Hughes
HHH
+$1.86M
3
DAL icon
Delta Air Lines
DAL
+$1.2M
4
DD icon
DuPont de Nemours
DD
+$1.13M
5
AB icon
AllianceBernstein
AB
+$1.08M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$715K
2
ATCO
Atlas Corp.
ATCO
+$693K
3
HTZ icon
Hertz Global Holdings, Inc.
HTZ
+$495K
4
IIPR icon
Innovative Industrial Properties
IIPR
+$427K
5
MBAI icon
MBody AI Ltd. Ordinary Share
MBAI
+$349K

Sector Composition

Rank Sector Weight
1 Healthcare 73.39%
2 Financials 8.14%
3 Technology 3.76%
4 Real Estate 3.58%
5 Industrials 2.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
VIVE
51
DELISTED
VIVEVE MED INC
VIVE
$391K 0.16%
+54
New +$403K
2017 Q2
0 quarters
STML
52
DELISTED
Stemline Therapeutics, Inc.
STML
$384K 0.16%
41,692
+31,692
+317% +$264K
2017 Q1
1 quarter
GBT
53
DELISTED
Global Blood Therapeutics, Inc.
GBT
$348K 0.15%
+12,724
New +$379K
2017 Q2
0 quarters
PCSB
54
DELISTED
PCSB Financial Corporation
PCSB
$341K 0.14%
+20,000
New +$337K
2017 Q2
0 quarters
CHRS icon
55
Coherus Oncology
CHRS
$156M
$320K 0.13%
+22,320
New +$429K
2017 Q2
0 quarters
AXGN icon
56
Axogen
AXGN
$2.05B
$317K 0.13%
18,898
+5,349
+39% +$72.1K
2017 Q1
1 quarter
ANCB
57
DELISTED
Anchor Bancorp
ANCB
$307K 0.13%
12,250
– –
2013 Q2
16 quarters
REED icon
58
DELISTED
Reeds, Inc. Common Stock
REED
$288K 0.12%
+2,352
New +$387K
2017 Q2
0 quarters
TTE icon
59
TotalEnergies
TTE
$200B
$261K 0.11%
5,260
– –
2013 Q2
16 quarters
KO icon
60
Coca-Cola
KO
$400B
$260K 0.11%
5,800
– –
2013 Q2
16 quarters
RLOG
61
DELISTED
Rand Logistics, Inc.
RLOG
$259K 0.11%
664,435
– –
2013 Q2
16 quarters
MDLZ icon
62
Mondelez International
MDLZ
$81.4B
$255K 0.11%
5,900
– –
2013 Q2
16 quarters
ARRY icon
63
DELISTED
Array Biopharma Inc
ARRY
$238K 0.1%
28,400
+16,400
+137% +$134K
2017 Q1
1 quarter
BLCM
64
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$233K 0.1%
1,998
+940
+89% +$117K
2017 Q1
1 quarter
HTZ icon
65
DELISTED
Hertz Global Holdings, Inc.
HTZ
$173K 0.07%
17,265
-46,040
-73% -$495K
2016 Q4
2 quarters
BCTF
66
DELISTED
Bancorp 34, Inc. Common Stock
BCTF
$140K 0.06%
10,000
– –
2016 Q4
2 quarters
ORIT
67
DELISTED
Oritani Financial Corp. New
ORIT
$133K 0.06%
7,800
– –
2013 Q2
16 quarters
FNB icon
68
FNB Corp
FNB
$6.14B
$126K 0.05%
8,905
– –
2014 Q3
11 quarters
CUZ icon
69
Cousins Properties
CUZ
$4.53B
$118K 0.05%
3,357
– –
2015 Q1
9 quarters
BMY icon
70
Bristol-Myers Squibb
BMY
$124B
$102K 0.04%
1,822
+100
+6% +$5.44K
2017 Q1
1 quarter
MDT icon
71
Medtronic
MDT
$121B
$93K 0.04%
1,050
– –
2014 Q3
11 quarters
MRK icon
72
Merck
MRK
$362B
$83K 0.03%
1,362
– –
2014 Q2
12 quarters
TST
73
DELISTED
TheStreet, Inc.
TST
$83K 0.03%
10,060
– –
2013 Q2
16 quarters
AEHL icon
74
Antelope Enterprise Holdings
AEHL
$202M
– –
0
– –
2013 Q2
16 quarters
CC icon
75
Chemours
CC
$1.92B
$51K 0.02%
1,360
– –
2015 Q3
7 quarters
1 2
3
4

Similar funds

FA
FMA Advisory Harrisburg, Pennsylvania $268M AUM 30.8% 1-Year Est. Return
KCP
KDI Capital Partners Raleigh, North Carolina $290M AUM 26.07% 1-Year Est. Return
HCIA
Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return
ISG
Investment Security Group Denver, Colorado $252M AUM 28.26% 1-Year Est. Return
TPCM
Three Peaks Capital Management Castle Rock, Colorado $301M AUM 43.39% 1-Year Est. Return
DCM
DeGreen Capital Management Scottsdale, Arizona $301M AUM 17.24% 1-Year Est. Return
MCL
MIK Capital LP New York $247M AUM 78.02% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

David M. Knott's Q2 2017 Portfolio in Review

As of Q2 2017, David M. Knott held 94 positions worth $240M, up 15% from $208M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

David M. Knott deployed $17.7M of net new capital in Q2 2017, opening 15 new positions and adding to 22 existing holdings. Its largest new stake was Howard Hughes: 15,735 shares worth $1.84M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 75% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $715K trimmed.

  • David M. Knott's largest Q2 2017 buy was Howard Hughes: 15,735 shares worth $1.84M.
  • David M. Knott added most to Pfizer in Q2 2017, an estimated $2.06M increase.
  • David M. Knott's biggest Q2 2017 reduction was Acadia Pharmaceuticals, cutting an estimated $715K.
  • David M. Knott fully exited Atlas Corp. in Q2 2017, selling an estimated $693K.
  • David M. Knott's ten largest holdings make up 80% of its $240M portfolio in Q2 2017.
  • David M. Knott opened 15 new positions and closed 4 in Q2 2017.
  • David M. Knott's portfolio value rose 15% quarter-over-quarter to $240M.

Based on David M. Knott's 13F filing for Q2 2017, filed 11 Aug 2017.